Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Dermatologic 3Thoracic 2Sarcoma 2Breast 2Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 20Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Neoplasms 4Urinary Bladder Neoplasms 3Ovarian Neoplasms 3Carcinoma, Merkel Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 12Nivolumab 10cemiplimab 5avelumab 5Ipilimumab 5atezolizumab 4poly ICLC 3fludarabine 3durvalumab 3Gemcitabine 3Cyclophosphamide 3Biopsy 3utomilumab 2ulixertinib 2pertuzumab 2osimertinib 2aldesleukin 2Trastuzumab 2Standard of Care 2Sirolimus 2Radiosurgery 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2Disulfides 2Blood Specimen Collection 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × poly ICLC × Dermatologic × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech SE

Phase 1 Completed
34 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡